The most prevalent and consistent dose-limiting side effects observed across studies of FGF21 analogs in patients with metabolic disease are gastrointestinal (GI), including mild-to-moderate nausea and diarrhea (183, 245, 246, 298, 301). Here, FGF21 is linked to Other metabolic disease.